6589 Stock Overview
Operates as a contract development and manufacturing company in Taiwan and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
EirGenix Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$80.90 |
| 52 Week High | NT$100.50 |
| 52 Week Low | NT$66.90 |
| Beta | 0.65 |
| 1 Month Change | 12.83% |
| 3 Month Change | -6.58% |
| 1 Year Change | -15.73% |
| 3 Year Change | -21.46% |
| 5 Year Change | 221.03% |
| Change since IPO | 79.82% |
Recent News & Updates
Shareholder Returns
| 6589 | TW Life Sciences | TW Market | |
|---|---|---|---|
| 7D | 3.9% | 1.5% | 0.5% |
| 1Y | -15.7% | -16.2% | 28.2% |
Return vs Industry: 6589 matched the TW Life Sciences industry which returned -16.2% over the past year.
Return vs Market: 6589 underperformed the TW Market which returned 28.2% over the past year.
Price Volatility
| 6589 volatility | |
|---|---|
| 6589 Average Weekly Movement | 5.7% |
| Life Sciences Industry Average Movement | 5.7% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in TW Market | 7.8% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 6589 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 6589's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | n/a | Lee-Cheng Liu | www.eirgenix.com |
EirGenix Inc. operates as a contract development and manufacturing company in Taiwan and internationally. The company offers cell line development, process development, analytical and quality control, cGMP manufacturing mammalian and microbial system, and antibody-drug conjugate services. It is also involved in the development of EG12014/EGI014, a Trastuzumab biosimilar, indicated for the treatment of cancer and currently under biologics license application status; EG1206A, a Pertuzumab biosimilar, indicated for the treatment of cancer and currently under Phase I stage; EG13074, indicated for the treatment of cancer and currently under Preclinical stage; TSY0110(EG12043), an antibody-drug conjugate, indicated for the treatment of cancer and currently under Preclinical stage; EG12021, Bevacizumab biosimilar, indicated for the treatment of cancer and currently under Preclinical stage; and EG62054, a biosimilar, currently under Preclinical stage.
EirGenix Inc. Fundamentals Summary
| 6589 fundamental statistics | |
|---|---|
| Market cap | NT$24.87b |
| Earnings (TTM) | -NT$986.69m |
| Revenue (TTM) | NT$1.17b |
21.2x
P/S Ratio-25.1x
P/E RatioIs 6589 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6589 income statement (TTM) | |
|---|---|
| Revenue | NT$1.17b |
| Cost of Revenue | NT$891.55m |
| Gross Profit | NT$279.34m |
| Other Expenses | NT$1.27b |
| Earnings | -NT$986.69m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.22 |
| Gross Margin | 23.86% |
| Net Profit Margin | -84.27% |
| Debt/Equity Ratio | 6.0% |
How did 6589 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/20 09:52 |
| End of Day Share Price | 2025/01/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
EirGenix Inc. is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jianzheng Wu | Capital Securities Corporation |
| null null | KGI Securities Co. Ltd. |
| Hsuan Chen | KGI Securities Co. Ltd. |